Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Suven Life SciencesBOM:530239 +2.24%41 PB Ratio is 13.66 as of Aug. 03, 2026, which is 242% above its 10-year median of 3.99. GuruFocus rates BOM:530239 with a GF Score™ of 41/100 and a GF Value™ of ₹97.09 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 923 Drug Manufacturers companies, Suven Life Sciences ranks worse than 95.23% on this metric.
The historical rank and industry rank for Suven Life Sciences's PB Ratio or its related term are showing as below:
BOM:530239'
s PB Ratio Range Over the Past 10 Years
Min: 0.2 Med: 3.99 Max: 48.51
Current: 13.66
During the past 13 years, Suven Life Sciences's highest PB Ratio was 48.51. The lowest was 0.20. And the median was 3.99.
BOM:530239's PB Ratio is ranked worse than 95.23% of 923
companies
in the Drug Manufacturers industry
Industry Median: 1.89
vs BOM:530239: 13.66
During the past 12 months, Suven Life Sciences's average Book Value Per Share Growth Rate was 344.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 9.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 13.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -14.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Suven Life Sciences was 59.50% per year. The lowest was -48.00% per year. And the median was 5.00% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Suven Life Sciences PB Ratio Related Terms
Suven Life Sciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Suven Life Sciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Suven Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suven Life Sciences PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Suven Life Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Suven Life Sciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Suven Life Sciences (BOM:530239) has a PB Ratio of 13.66 as of Aug. 03, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Suven Life Sciences and its competitors. This is 242% above median its historical median of 3.99. Over the past decade, Suven Life Sciences' PB Ratio has ranged from 0.20 to 48.51. According to the industry distribution chart, Suven Life Sciences ranks #879 out of 923 companies in the Drug Manufacturers industry, placing it in the top 95.2%.
Is Suven Life Sciences' PB Ratio too high?
Suven Life Sciences' current PB Ratio of 13.66 is 242% above median its 10-year median of 3.99. Over the past 10 years, this metric has ranged from a low of 0.20 to a high of 48.51. The Drug Manufacturers industry median PB Ratio is 1.89. Suven Life Sciences' value of 13.66 is 622.8% above this industry median. Based on the distribution chart, Suven Life Sciences ranks #879 out of 923 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Suven Life Sciences has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Suven Life Sciences' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Suven Life Sciences ranks #879 out of 923 companies for PB Ratio. This places Suven Life Sciences in the lower half of its industry. The industry median PB Ratio is 1.89. Suven Life Sciences' value of 13.66 is 622.8% above this benchmark. Historically, Suven Life Sciences' own PB Ratio has ranged from 0.20 to 48.51 over the past decade. While the company's 10-year median is 3.99 vs. the industry median of 1.89, Suven Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.89, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Suven Life Sciences's current PB Ratio of 13.66 is 622.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Suven Life Sciences and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suven Life Sciences's current PB Ratio is 13.66, which is 242% above median its own 10-year median of 3.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suven Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Suven Life Sciences (BOM:530239) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹97.09, compared to a current price of ₹306.30 — trading 215.5% above its estimated fair value. The current PB Ratio is 13.66, which is 242% above median its 10-year median of 3.99 and 622.8% above the Drug Manufacturers industry median of 1.89. Suven Life Sciences' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Suven Life Sciences (BOM:530239), the current PB Ratio is 13.66 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suven Life Sciences (BOM:530239) Overvalued in 2026?
Based on GuruFocus' analysis, Suven Life Sciences stock appears to be overvalued.
The current stock price of ₹306.30 is trading 215.5% above its estimated GF Value™ of ₹97.09.
GuruFocus considers Suven Life Sciences to be Significantly Overvalued.
Key valuation signals for BOM:530239:
PB Ratio: 13.66 (242% above median its 10-year median of 3.99)
GF Value™: ₹97.09 vs. price of ₹306.30 (215.5% above fair value)
Industry Position: 622.8% above the Drug Manufacturers median (#879 of 923)
No single metric tells the full story. See the BOM:530239 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suven Life Sciences Ltd is an India-based biopharmaceutical company. The company is focused on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The company's only segment is providing Research and Development services. The company's geographical segment includes India; the USA; Europe and Others. The company generates maximum revenue from the USA. The company earns revenue from the sale of New Chemical Entity (NCE) based Intermediates for CNS disorders.
41GF Score
Get the complete analysis for BOM:530239
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530239 has been successfully added to your 
